

02-07-00

PTO/SB/05 (12/97)

Approved for use through 09/30/00. OMB 0651-0032

A

02/04/00
U.S. PTO

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No.	249/127
First named Inventor or Application Identifier	Dr. Paddy Jim Baggot
Title	TREATMENT OF CHROMOSOMAL ABNORMALITIES IN FETUSES THROUGH A COMPREHENSIVE METABOLIC ANALYSIS OF AMNIOTIC FLUID
Express Mail Label No.	EL 49651540US

(Only for new nonprovisional applications under 37 CFR 1.53(b))

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contacts

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

1. ☐ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. + Specification [Total Pages 24]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☐ Drawing(s) (35 USC § 113) [Total Sheets]
4. ☒ Oath or Declaration [Total Sheets]
 - ☒ Newly executed (original or copy)
 - ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
(Note Box 5 below)
 - i. ☐ DELETION OF INVENTORS
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 CFR 1.53(d)(2) and 1.53(b).

5. ☐ Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission
(If applicable, all necessary)
 - a. ☐ Computer readable Copy
 - b. ☐ Paper Copy (Identical to computer copy)
 - c. ☐ Statement verifying identity of above copies

jc:564 U.S. PTO
09/499006
02/04/00

ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment Papers (cover sheet & document(s))
8. ☐ 37 CFR 3.73(b) Statement + Power of Attorney
(when there is an assignment)
9. ☐ English Translation Document (if applicable)
10. ☐ Information Disclosure ☐ Copies of IDS
Statement (IDS) PTO-1449 Citations
11. ☐ Preliminary Amendment
12. + Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
13. ☐ Small Entity Statement filed in prior application
Statement(s) Status still proper and desired
14. ☐ Certified Copy of Priority Document(s)
(If foreign priority is claimed)
15. ☐ Other:

NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28)

16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment.

☐ Continuation ☐ Divisional ☐ Continuation-in-Part of prior application No: _____

Prior application information: Examiner _____ Group / Art Unit _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

X Customer Number or Bar Code Label	22249	or <input type="checkbox"/> Correspondence address below
(insert Customer No. or Attach bar code label here)		

NAME	Polaphat Veravanich 45,179				
	Lyon & Lyon LLP				
ADDRESS	633 West Fifth Street				
	Suite 4700				
CITY	Los Angeles	STATE	California	ZIP CODE	90071-2066
COUNTRY	U.S.A.	TELEPHONE	949-567-2300	FAX	949-567-6600

Name (Print/Type)	Polaphat Veravanich	Registration No. (Attorney/Agent)	45,179
Signature	<i>Paul Veravanich</i>	Date	February 4, 2000